Conference Reports

By Eric Ramos

CHICAGO -- June 12, 2020 -- An intra-articular injection of JTA-004, a novel enhanced protein solution that is supplemented with hyaluronic acid and clonidine, improved pain in patients with knee osteoarthritis, according to a study presented at the 2020 Virtual Meeting of...

By Eric Ramos

CHICAGO -- June 11, 2020 -- A set of antibody biomarkers can help predict which patients with rheumatoid arthritis (RA) will respond to therapy, according to a study presented at the 2020 Virtual Meeting of the European League Against Rheumatism (EULAR).

“For...

By Eric Ramos

CHICAGO -- June 9, 2020 -- Long-term treatment with canakinumab was safe and effective for patients with colchicine-resistant familial Mediterranean fever, according to a study presented at the 2020 Virtual Meeting of the European League Against Rheumatism (EULAR).

“...

By Eric Ramos

CHICAGO -- June 9, 2020 -- Therapeutic drug monitoring in patients with rheumatic diseases who are starting treatment with infliximab does not appear to be superior to standard treatment in order to achieve remission, according to a study presented at the 2020 Virtual...

By Eric Ramos

CHICAGO -- June 8, 2020 -- Colchicine 1 mg/day for 12 weeks was not effective in improving pain, tender and swollen joint count, or grip strength in patients with symptomatic hand osteoarthritis, according to a study presented at the 2020 Virtual Meeting of the European...

By Eric Ramos

CHICAGO -- June 8, 2020 -- Adding belimumab to standard therapy significantly improves renal responses in patients with active lupus nephritis, compared with standard therapy alone, according to a study presented at the 2020 Virtual Meeting of the European League Against...

By Eric Ramos

CHICAGO -- June 7, 2020 -- Recommendations on the use of intra-articular injections of platelet-rich plasma for knee osteoarthritis (OA) were presented at the 2020 Virtual Meeting of the European League Against Rheumatism (EULAR) by an international multidisciplinary task...

By Jill Stein

PARIS -- April 9, 2019 -- Children with X-linked hypophosphataemia (XLH) experience larger improvements in rickets and other outcomes when treated with the investigational agent burosumab than with conventional treatment, according to a study presented here at the 2019 World...

By Jill Stein

PARIS -- April 8, 2019 -- Achieving a higher SARC-F score at the time of admission to general rehabilitation is associated with increased functional dependence, according to results of a cross-sectional study presented here at the 2019 World Congress on Osteoporosis,...

By Jill Stein

PARIS -- April 8, 2019 -- Burosumab significantly reduces measures of osteomalacia in adults with X-linked hypophosphataemia (XLH), according to results of a phase 3, open-label, single-arm study reported here on April 5 at the 2019 World Congress on Osteoporosis,...

Pages